IMMURON (IMRN) vs Senti Biosciences, Inc. (SNTI)
IMMURON and Senti Biosciences, Inc. are both Biotechnology companies. IMMURON and Senti Biosciences, Inc. are of similar size ($10.0M and $9.6M). IMMURON grew revenue faster over the last twelve months: −6.62% against −70.7%. IMMURON has the higher net margin (−262.7% vs −3,789.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, IMMURON leads on 10 and Senti Biosciences, Inc. on 3.
Valuation
Profitability
| Metric | IMRN | SNTI | Biotechnology median |
|---|---|---|---|
| Gross margin | 71.28% | 100.00% | 65.16% |
| Operating margin | 0.00% | (4,181.12%) | 0.00% |
| Net margin | (262.71%) | (3,789.30%) | 0.00% |
| Free cash flow margin | 0.00% | (2,900.38%) | 0.00% |
| Return on equity | 0.00% | (466.46%) | (57.72%) |
| Return on assets | 0.00% | (97.52%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack